Trending...
- California: Governor Newsom signs legislation 7.3.25
- California: Governor Newsom proclaims Independence Day 2025
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
A novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- RIVERSIDE, CA – Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, announces that the U.S. Patent Office has issued Patent Application No. 17/837,917 for the "Therapeutic Agent for Treatment of Age-Related Macular Degeneration" and for the registration of the trade name "CTZ1™", the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. As a Vascular Disruptive Agent, CTZ1™ can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1 is a lead candidate for the treatment of neovascular age-related macular degeneration. To learn more about CTZ1™ as a therapeutic agent, visit our website here: citrustherapeutics.com or email salkayali@citrustherapeutics.com
CTZ1™ debuts from Citrus Therapeutics, LLC, based in Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor. Citrus Therapeutics, LLC was formed to develop, research, and promote innovative multi-pharmacophore therapies.
David RP Almeida, MD MBA PhD, is a Board-Certified Ophthalmologist and Vitreoretinal Surgeon. Dr. Almeida is involved in diagnosing and treating conditions of the vitreous, retina, and macula. Dr. Almeida is Director of Clinical Research at Erie Retina Research and Medical Director for Ophthalmology Research at The Clinical Trials Network. Dr. Almeida is Chief Medical Editor of the online publication Eyes on Eyecare, ophthalmology division.
More on The Californer
Eric K. Chin, M.D., Board-Certified ophthalmologist, is a graduate of the University of California Berkeley and Chicago Medical School. Dr. Chin was awarded several accolades for teaching and research on treatments for various retinal diseases. Dr. Chin is a partner at Retina Consultants of Southern California and serves as Clinical Faculty at Loma Linda University and Loma Linda Veterans Affairs Hospital.
Mr. Ahmad Alkayali is a renowned and trusted leader in developing and manufacturing natural ingredients for foods, beverages, and supplements. Mr. Alkayali is the original inventor of three Collagen Type II patents for dietary supplements and the first to introduce Collagen Types I, II, and III food supplements to the Health Food Industry more than 35 years ago. Mr. Alkayali's inventions and elements are incorporated into nutritional products that are recognized globally for cardiovascular, joint, skin, anti-aging, and eye health.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. As a Vascular Disruptive Agent, CTZ1™ can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- Colbert Packaging Announces WBENC Recognition
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Over the past three months, California seized $476 million worth of unlicensed cannabis products
- California scores more clean energy records: 9 in 10 days this year partially powered by 100% clean energy
- "Mobile Suit Gundam" Takes Over San Diego Comic-Con 2025
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1 is a lead candidate for the treatment of neovascular age-related macular degeneration. To learn more about CTZ1™ as a therapeutic agent, visit our website here: citrustherapeutics.com or email salkayali@citrustherapeutics.com
CTZ1™ debuts from Citrus Therapeutics, LLC, based in Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor. Citrus Therapeutics, LLC was formed to develop, research, and promote innovative multi-pharmacophore therapies.
David RP Almeida, MD MBA PhD, is a Board-Certified Ophthalmologist and Vitreoretinal Surgeon. Dr. Almeida is involved in diagnosing and treating conditions of the vitreous, retina, and macula. Dr. Almeida is Director of Clinical Research at Erie Retina Research and Medical Director for Ophthalmology Research at The Clinical Trials Network. Dr. Almeida is Chief Medical Editor of the online publication Eyes on Eyecare, ophthalmology division.
More on The Californer
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- Hamilton Zanze Sponsors the Acquisition of Two Garden-Style Communities in Reno Area
- Meet a Scientologist Captures Greece's Timeless Beauty with Videographer Lambros Malamas
Eric K. Chin, M.D., Board-Certified ophthalmologist, is a graduate of the University of California Berkeley and Chicago Medical School. Dr. Chin was awarded several accolades for teaching and research on treatments for various retinal diseases. Dr. Chin is a partner at Retina Consultants of Southern California and serves as Clinical Faculty at Loma Linda University and Loma Linda Veterans Affairs Hospital.
Mr. Ahmad Alkayali is a renowned and trusted leader in developing and manufacturing natural ingredients for foods, beverages, and supplements. Mr. Alkayali is the original inventor of three Collagen Type II patents for dietary supplements and the first to introduce Collagen Types I, II, and III food supplements to the Health Food Industry more than 35 years ago. Mr. Alkayali's inventions and elements are incorporated into nutritional products that are recognized globally for cardiovascular, joint, skin, anti-aging, and eye health.
Source: Citrus Therapeutics
Filed Under: Health
0 Comments
Latest on The Californer
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Local Pub Grows Unique Community Ownership Program
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- California: Acting Governor Eleni Kounalakis proclaims Disability Pride Month
- CHRIS EDMONDS JOINS CITY NATIONAL BANK AS EXECUTIVE VICE PRESIDENT, HEAD OF COMMERCIAL AND NATIONAL CORPORATE BANKING
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- California: $35 million to law enforcement partners to keep communities safe from impaired driving
- Curtis Sergeant's Book The Only One Continues to Equip Christians to Live Fully in by and for God
- IFYA Announces New Froyo Heaven Art Contest
- BKM Capital Partners Publishes Case Study on Hughes Airport Center, Showcasing Strategic Value-Add Execution in Las Vegas
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- Auto Careers Online Secures Top Dealers' Choice Award for Eighth Consecutive Year
- MANTL Becomes First Fintech to Offer Plaid Layer
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- California: Governor Newsom commits $101 million to jumpstart critical rebuilding efforts after LA Fires
- Stash Proof Launches Free Shipping on All Orders Nationwide
- John Duffy Hosts Sister Irene O' Neill, Founder and President, and Kelly Mallon Young
- Changzhou Huifeng Vehicle Parts Factory expands U.S. distribution operations
- California: Governor Newsom announces additional crews to assist Texas search and rescue operations